881 related articles for article (PubMed ID: 11700073)
1. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
2. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
Blanpain C; Buser R; Power CA; Edgerton M; Buchanan C; Mack M; Simmons G; Clapham PR; Parmentier M; Proudfoot AE
J Leukoc Biol; 2001 Jun; 69(6):977-85. PubMed ID: 11404385
[TBL] [Abstract][Full Text] [Related]
3. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
Blanpain C; Doranz BJ; Bondue A; Govaerts C; De Leener A; Vassart G; Doms RW; Proudfoot A; Parmentier M
J Biol Chem; 2003 Feb; 278(7):5179-87. PubMed ID: 12466283
[TBL] [Abstract][Full Text] [Related]
4. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
Wu L; LaRosa G; Kassam N; Gordon CJ; Heath H; Ruffing N; Chen H; Humblias J; Samson M; Parmentier M; Moore JP; Mackay CR
J Exp Med; 1997 Oct; 186(8):1373-81. PubMed ID: 9334377
[TBL] [Abstract][Full Text] [Related]
5. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
[TBL] [Abstract][Full Text] [Related]
6. The seventh transmembrane domain of cc chemokine receptor 5 is critical for MIP-1beta binding and receptor activation: role of MET 287.
Youn BS; Yu KY; Alkhatib G; Kwon BS
Biochem Biophys Res Commun; 2001 Mar; 281(3):627-33. PubMed ID: 11237703
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
[TBL] [Abstract][Full Text] [Related]
8. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium.
Yamagami S; Hamrah P; Miyamoto K; Miyazaki D; Dekaris I; Dawson T; Lu B; Gerard C; Dana MR
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1201-7. PubMed ID: 15790880
[TBL] [Abstract][Full Text] [Related]
9. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
10. Recognition of RANTES by extracellular parts of the CCR5 receptor.
Duma L; Häussinger D; Rogowski M; Lusso P; Grzesiek S
J Mol Biol; 2007 Jan; 365(4):1063-75. PubMed ID: 17101151
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the chemokine receptor, CCR5.
Mueller A; Mahmoud NG; Goedecke MC; McKeating JA; Strange PG
Br J Pharmacol; 2002 Feb; 135(4):1033-43. PubMed ID: 11861332
[TBL] [Abstract][Full Text] [Related]
12. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
13. Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope.
Staudinger R; Wang X; Bandrés JC
Biochem Biophys Res Commun; 2001 Aug; 286(1):41-7. PubMed ID: 11485305
[TBL] [Abstract][Full Text] [Related]
14. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
Owais M; Arya SK
J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
[TBL] [Abstract][Full Text] [Related]
15. Viral macrophage inflammatory protein-II and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1.
Davis CN; Zujovic V; Harrison JK
Mol Pharmacol; 2004 Dec; 66(6):1431-9. PubMed ID: 15361546
[TBL] [Abstract][Full Text] [Related]
16. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
[TBL] [Abstract][Full Text] [Related]
17. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
[TBL] [Abstract][Full Text] [Related]
18. Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage-inflammatory protein-II (VMIP-II) reveals a fully monomeric protein.
LiWang AC; Cao JJ; Zheng H; Lu Z; Peiper SC; LiWang PJ
Biochemistry; 1999 Jan; 38(1):442-53. PubMed ID: 9890927
[TBL] [Abstract][Full Text] [Related]
19. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
Maeda Y; Foda M; Matsushita S; Harada S
J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction.
Zhou N; Luo Z; Hall JW; Luo J; Han X; Huang Z
Eur J Immunol; 2000 Jan; 30(1):164-73. PubMed ID: 10602038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
